BAVARIA Industriekapital AG Announces Acquisition Of Osny Oral Dose Manufacturing Business From Catalent




BAVARIA Industriekapital AG Announces Acquisition of Osny Oral Dose Manufacturing Business from Catalent

Date: 03/31/2009

Munich, Germany and Somerset, NJ, March 31, 2009 — BAVARIA Industriekapital AG, a German industrial holding company (“BAVARIA”), and Catalent Pharma Solutions today jointly announced the completion of the purchase of Catalent’s Osny, France oral manufacturing business by an affiliate of BAVARIA. Terms of the transaction, which is effective as of March 30th, were not disclosed.

The Osny business provides cGMP development and manufacturing services for hormonal and other high potent drugs in oral dose forms that are either approved for commercial marketing or in clinical development. The business expects to retain all employees associated with the business as of the closing, and to continue to serve all existing customers of the business. The business will become known as “Osny Pharma SAS” effective as of the closing.

Hans Magnus Andresen, Managing Director of BAVARIA, said, “BAVARIA is extremely excited about this acquisition. We have been very impressed by the management and operating teams in Osny and look forward to playing a vital part in the continuation of the site’s positive development. The site will focus strongly on keeping its loyal customer base satisfied and continuously optimize its production processes without losing its keen eye on delivering top quality products. Osny Pharma SAS has long standing traditions in this industry and is ideally positioned for continued growth – organically as well as through additional acquisitions.”

Ian Muir, Vice President and General Manager of Modified Release Technologies for Catalent, said, “We are pleased that BAVARIA has acquired this business, as we believe they, along with the strong local team in place, will continue to provide the facility’s customers the high degree of quality and compliance they have received in the past. We also appreciate the commitment BAVARIA has demonstrated to the future of the business, and to the dedicated employees at the site.”

About Osny Pharma
Osny Pharma SAS is a contract manufacturing company focused on providing development and manufacturing services for oral tablets and hard capsules, with particular emphasis on hormonal and highly potent pharmaceutical products.

About BAVARIA Industriekapital AG
BAVARIA Industriekapital AG is an industrial holding company which acquires low-profit companies throughout Europe. Through active restructuring and revitalization management it ensures the long-term success of the companies acquired. The extensive experience and know-how of its staff allow BAVARIA Industriekapital AG to restore even companies in difficult sectors to profitability. The majority of the stock of BAVARIA Industriekapital AG is family-owned and the company has been listed on the Entry Standard All Share Index of the German Stock Exchange since 2006. At present BAVARIA Industriekapital AG has holdings in nine companies and around 3,000 employees. In 2007 the group turnover amounted to Euro 410 million. The annual profit of BAVARIA Industriekapital was Euro 23 million. For more information, visit www.baikap.de .

About Catalent

Headquartered in Somerset, New Jersey, Catalent Pharma Solutions is a leading provider of advanced dose form and packaging technologies, and development, manufacturing and packaging services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes. Catalent employs approximately 9,100 at more than 30 facilities worldwide and in fiscal 2008 generated more than $1.8 billion in annual revenue. For more information, visit  www.catalent.com .

more products. better treatments. reliably supplied.™